$0.77
-0.03(-3.15%)
Mkt Cap $32M
$0.24
$2.97
52-Week Range
At A Glance
1
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer.
2
Most recently: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 4, 2026, Cypherpunk Technologies Inc. (the “Compan (2026-03-09).
$32M
Market Cap
$184.9K
Revenue
-$16M
Net Income
Employees52
Fundamentals
How The Business Makes Money
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001509745
ISINUS52187K2006
CUSIP52187K101
Phone617 714 0360
Address47 Thorndike Street, Cambridge, MA, 02141, US
SEC EDGAR